- Home
- CPZ vs MRVI Comparison
CPZ vs MRVI Comparison
Compare CPZ & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- MRVI
- Stock Information
- Founded
- CPZ 2019
- MRVI 2014
- Country
- CPZ United States
- MRVI United States
- Employees
- CPZ N/A
- MRVI N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CPZ Finance
- MRVI Health Care
- Exchange
- CPZ Nasdaq
- MRVI Nasdaq
- Market Cap
- CPZ 328.1M
- MRVI 371.8M
- IPO Year
- CPZ N/A
- MRVI 2020
- Fundamental
- Price
- CPZ $16.45
- MRVI $2.45
- Analyst Decision
- CPZ
- MRVI Hold
- Analyst Count
- CPZ 0
- MRVI 10
- Target Price
- CPZ N/A
- MRVI $5.84
- AVG Volume (30 Days)
- CPZ 63.0K
- MRVI 1.5M
- Earning Date
- CPZ 01-01-0001
- MRVI 08-11-2025
- Dividend Yield
- CPZ 11.07%
- MRVI N/A
- EPS Growth
- CPZ N/A
- MRVI N/A
- EPS
- CPZ N/A
- MRVI N/A
- Revenue
- CPZ N/A
- MRVI $219,830,000.00
- Revenue This Year
- CPZ N/A
- MRVI N/A
- Revenue Next Year
- CPZ N/A
- MRVI $10.70
- P/E Ratio
- CPZ N/A
- MRVI N/A
- Revenue Growth
- CPZ N/A
- MRVI N/A
- 52 Week Low
- CPZ $13.17
- MRVI $1.67
- 52 Week High
- CPZ $16.11
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- CPZ 51.68
- MRVI 50.12
- Support Level
- CPZ $16.37
- MRVI $2.35
- Resistance Level
- CPZ $16.69
- MRVI $2.71
- Average True Range (ATR)
- CPZ 0.20
- MRVI 0.17
- MACD
- CPZ -0.02
- MRVI 0.01
- Stochastic Oscillator
- CPZ 46.97
- MRVI 57.50
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.